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INTRODUCTION
Artesunate and other artemisinin derivatives such as artemether, and dihydroartemisinin are potent drugs which are used in the management of uncomplicated malaria. Artesunate is the most widely used of the artemisinin derivatives 1 . The use of any of the artemisinins as monotherapy has, however, been discouraged by the WHO to minimise the development of resistance to these new antimalarials. Instead, the WHO has since 2001 recommended the use of artemisininbased combination therapy (ACT) as first line malaria treatment in malaria-endemic African countries. In Ghana, artesunate-amodiaquine is the ACT of choice 2 . The cure rate from monotherapy with artesunate and other artemisinin derivatives is low compared to the use of ACT 3 . In spite of the recommendation from the WHO, monotherapy with artesunate tablets is commonly employed in the management of malaria in Ghana and many other countries in Africa 4, 5 . Whether employed as monotherapy or as a component of ACT, artesunate plays a pivotal role in the global fight against malaria, hence there is the need to guarantee its quality and eliminate any form of fakery or counterfeiting. Already there have been several reports cataloguing the distribution and use of counterfeit and substandard artesunate tablets in many South-East Asian countries [6] [7] [8] [9] [10] [11] . Many African countries lack the resources to employ advanced techniques such as high performance liquid chromatography; mass spectrometry and Raman spectroscopy 12 which can be used to ascertain the authenticity of artemisinin products in the market and are therefore vulnerable to counterfeiting and substandard drugs. Also, artesunate and other artemisinins, being generally expensive drugs, are potential targets of counterfeiting. As a result of the above factors, Africa has been cited as the next possible destination for counterfeit and substandard artemisinins 10 . Already, cases of counterfeit and substandard artemisinins have been reported in African countries such as Tanzania, Cameroon In Ghana, artesunate tablet is the commonest artemisinin product in the market and is available in various strengths from both local and foreign manufacturers. The quality of these antimalarials if not properly safeguarded could lead to therapeutic failure in patients and the development of drug resistance. The objective of this study was, therefore, to evaluate the quality of artesunate tablets available in community and wholesale pharmacies in Kumasi, Ghana. The study also sought to determine the existence or otherwise of counterfeit or fake artesunate tablets in the study area. 
EXPERIMENTAL

Uniformity of weight and disintegration of tablets
The uniformity of weight was determined as the relative standard deviation of twenty randomly selected artesunate tablets. The disintegration times of six randomly selected tablets was determined in distilled water at 37 ± 0.5 °C using an Erweka tablet disintegration tester (Type ZT3/1, Heusenstamm, Germany).
Breaking strength and friability of tablets
The breaking strength of ten randomly selected tablets was determined using a Schleuniger hardness tester (Schleuniger and Co., Switzerland). The friability (%) of ten randomly selected tablets was determined using an Erweka friabilator (Erweka TA20, England) operated at 25 rpm for 4 minutes.
Qualitative test on artesunate tablets
A test for the presence or absence of artesunate in the tablets, which was meant to distinguish genuine artesunate from counterfeit ones, was carried out using a colorimetric field method for the qualitative testing of artesunate in tablets (standard test) 13 .
Assay of artesunate tablets
Artesunate tablets were quantitatively analysed using a previously described and validated colorimetric method with minor modifications 1 . A number of artesunate tablets (2-5, depending on artesunate brand) were crushed into powder in a porcelain mortar with a pestle. Artesunate powder equivalent to 0.1 g artesunate was weighed into a 100 ml volumetric flask. A quantity of 1M sodium hydroxide was added to the artesunate powder to the 40 ml mark and allowed to stand for 20 min to hydrolyse the drug. The sample was filtered with a sintered glass filter into a 100 ml volumetric flask and to the filtrate was added 40 ml of 1.1 M acetic acid, followed by 20 ml of 5mg/ml Fast Red TR. The resultant solution was allowed to stand for 5 min to form a yellowish solution. The amount of artesunate in the final solutions formed were assayed spectrophotometrically (Cecil 8000 Series, Cecil Instruments, Cambridge, England) at 420 nm with the use of regression data obtained from a calibration plot of artesunate powder (r 2 = 0.9941). The tests were repeated twice and the results presented are the mean of three determinations. The whole procedure was repeated for the different brands of artesunate tablets.
RESULTS
The shelf life of the artesunate tablets ranged from 2 to 4 years. Table 1 shows the country of manufacture and the mechanical properties of the artesunate tablets. The country of manufacture was indicated for all the samples, except for ART 1. The percentage weight deviation of the various brands of artesunate from their respective mean weights was less than 10%. The mean tablet weight for 25 mg, 50 mg, 100 mg and 200 mg strength artesunate brands was 203.5 ± 7.45 mg (n =1), 287.1 ± 57.2 mg (n = 11), 309.9 ± 83.6 mg (n = 4) and 566.2 ± 9.05 mg (n = 1), respectively. The breaking strength of the tablets ranged from 2.5-17.2 kg/cm 2 . Only ART 13 and ART 15 had breaking strength values lower than 4.0 kg/cm 2 . The percentage friability was lower than 1 % w/w (range: 0.04-0.85 % w/w) for all the tablets tested. All the tablets disintegrated in aqueous medium in less than 5 minutes (range: 41 ± 1.82 -257 ± 13.5 s). Qualitative tests on all the different brands of artesunate tablets resulted in the formation of a yellowish product of varying colour intensity. Table 2 depicts the content of artesunate in the tablets. The percentage artesunate content ranged from 47.9 to 99.9 %. Six (35.3 %) of the tablets had artesunate content ≥ 90 % while eleven (64.7 %) had artesunate content <90 % of the label claim. On the other hand, three (17.6 %) of the samples had artesunate content ≥ 95 % while fourteen (82.4 %) was <95%.
DISCUSSION
The country of manufacture was indicated on the packaging of all the brands of artesunate tablets except for ART 1 where the only address given was that of the dealer/marketing agent in the United Kingdom. This observation makes ART 1 a product of doubtful quality. All the tablets sampled were within their shelf life at the time of the study. Physical examination of the product packaging and the artesunate tablets of the other brands did not give any indication of fakery or counterfeiting. Qualitative tests on the artesunate tablets using the Fast Red TR dye technique also produced yellowish coloured products signifying the presence of artesunate in all the artesunate tablet brands. Thus, none of the tablets tested was found to be counterfeit. Counterfeit drugs have been defined by the WHO as drugs which are 'deliberately and fraudulently mislabelled with respect to identity or source and occur with branded and generic products and may include products with the correct ingredients but fake packaging, with the wrong ingredients, without active ingredients or with insufficient active ingredients' 14 . Variation in colour intensity of the samples indicates a variation in the amount of artesunate contained in the different brands of artesunate tablets, signifying the possibility of substandard tablets. Substandard drugs have been defined as medicines that have been manufactured below established standards of quality 14 . Most of the tablets possessed appropriate mechanical properties in terms of weight uniformity, breaking strength, friability and disintegration time ( Table 1 ). The different brands of artesunate tablets showed acceptable weight uniformity with weight deviations less than 10 %w/w. The breaking strength of the tablets was ≥ 4 kg/cm 2 except for ART 13 (3.4 kg/cm 2 ) and ART 15 (2.5 kg/cm 2 ). Thus, ART 13 and ART 15 failed the breaking strength test. The breaking strength is used to characterise the hardness of tablets. Tablets with breaking strength values ≥ 4 kg/cm 2 have acceptable hardness. The friability of all the artesunate brands was <1% w/w and the disintegration times were less than 15 minutes, thus all the artesunate brands passed the friability and disintegration tests. It could thus be inferred that all the artesunate brands studied could withstand abrasion without loss of tablet integrity and could disintegrate readily in aqueous medium, especially in the gastrointestinal tract. Quantitative analysis using absorbance measurements showed 6 (35.3 %) of the tablets passing and 11 (64.7 %) failing the WHO International Pharmacopoeia requirement which specifies artesunate tablets to contain not less than 90.0 % and not more than 110.0 % of the amount of artesunate indicated on the label 15 . On the other hand, only 3 (17.6 %) of the samples passed the European Pharmacopoeia content specifications of 95-105 % of the active drug substance 17 while 14 (82.4 %) did not meet would result in sub-therapeutic levels of the drug in patients, leading to treatment failure and possible development of drug resistance. There is, therefore, the need for drug regulatory bodies in Ghana and other African countries to be vigilant and undertake routine assessment of the quality of artesunate and other artemisinin products on the market in order to flush out counterfeit and substandard ones.
CONCLUSION
No counterfeit or fake artesunate was found out of 17 brands of artesunate tablets sampled. Eleven of the samples were however found to be of substandard quality as they contained lower amounts of artesunate. Routine tests using the fast-red TR test (dye test) is invaluable in detecting counterfeit and substandard artesunate tablets on the market.
